Propranolol - Pierre Fabre

Drug Profile

Propranolol - Pierre Fabre

Alternative Names: Beta-blocker- Pierre-Fabre; Hemangeol; Hemangiol; M7030; M703101; Propanerol; Propranolol- Pierre-Fabre

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Bordeaux
  • Developer Maruho; Pierre Fabre
  • Class Antihypertensives; Antimigraines; Class II antiarrhythmics; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemangioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemangioma

Most Recent Events

  • 05 Oct 2017 Pierre Fabre plans a phase III trial for Haemangioma (In infants) in France (EudraCT2010-023488-16)
  • 20 Dec 2016 Pierre Fabre completes a phase III trial in Haemangioma (In infants) in Spain (PO) (EudraCT2014-005555-80) before December 2016
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top